Treace Medical Shareholders Back Directors, Pay and Auditor
At its annual meeting, Treace Medical Concepts shareholders re-elected three Class II directors for three-year terms, signaling continued support for the company's current board and strategic direction. Investors also approved the executive compensation program and ratified Grant Thornton LLP as the independent auditor, ensuring continuity in financial oversight. An analyst rating on TMCI stock is a Hold with a $2.00 price target, while TipRanks’ AI Analyst, Spark, rates it Neutral due to weak financial performance despite strong gross margins.
Treace Medical Concepts shareholders elect directors and approve key proposals
Treace Medical Concepts Inc. held its 2026 Annual Meeting of Stockholders, where shareholders elected Lance A. Berry, Elizabeth S. Hanna, and Jane E. Kiernan as Class II directors. They also approved the compensation for executive officers and ratified Grant Thornton LLP as the independent accounting firm for fiscal year 2026. The company recently reported better-than-expected Q1 2026 financial results, with shares gaining 11% in the past week and 15% year-to-date.
Treace Medical (TMCI) shareholders elect directors and ratify auditor at 2026 meeting
Treace Medical Concepts, Inc. (TMCI) stockholders elected three Class II directors, Lance A. Berry, Elizabeth S. Hanna, and Jane E. Kiernan, to serve three-year terms expiring at the 2029 annual meeting. Shareholders also approved, on an advisory basis, the compensation of the company’s named executive officers and ratified the appointment of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The decisions were made at the company's 2026 annual meeting held on May 19, 2026.
TMCI SEC Filings - Treace Medical Concepts, Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for investors and traders to access official regulatory documents for Treace Medical Concepts (TMCI), including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms. Recent filings detail beneficial ownership by Armistice Capital and Steven Boyd, as well as insider transactions for several company officers, including the CFO, C. Legal & Compliance Officer, Chief Innovation Officer, and SVP of Sales. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis for enhanced investor insight.
Treace Medical Concepts (TMCI) director awarded 30,000 RSUs
Treace Medical Concepts director Lance A. Berry was awarded 30,000 restricted stock units (RSUs) as an equity grant. These RSUs will vest 100% on the earlier of May 19, 2027, or the 2027 annual meeting of stockholders, provided he continues his service to the company. After this grant, Berry's direct holdings in Treace Medical Concepts total 74,593 shares, including the newly awarded RSUs.
Treace Medical (TMCI) awards 30,000 RSUs to company director
Treace Medical Concepts (TMCI) director Lawrence W. Hamilton was granted 30,000 restricted stock units (RSUs) as compensation, not via an open-market purchase. These RSUs will vest 100% on the earlier of May 19, 2027, or the 2027 annual meeting of stockholders, provided Hamilton remains with the company. He has elected to defer receiving the underlying shares until a change in control or his separation from service, bringing his total direct holdings to 74,056 shares.
Director at Treace Medical (TMCI) receives 30,000 restricted stock units
Deepti Jain, a director at Treace Medical Concepts (TMCI), has received a grant of 30,000 restricted stock units (RSUs) at no purchase price. These RSUs will vest 100% on the earlier of May 19, 2027, or the 2027 annual stockholders' meeting, contingent on her continued service. Following this transaction, Jain's total holdings, including the RSUs, amount to 100,243 common shares.
Armistice Capital (TMCI) discloses 6.36M shares, 9.85% stake
Armistice Capital, LLC and Steven Boyd have reported a 9.85% beneficial ownership stake in Treace Medical Concepts, Inc. (TMCI), totaling 6,364,000 shares of common stock. This disclosure was made via a Schedule 13G/A amendment, indicating that Armistice Capital, as the investment manager for Armistice Capital Master Fund Ltd., exercises shared voting and dispositive power over these shares. The filing clarifies the reporting persons and their responsibilities under an Investment Management Agreement, explicitly disclaiming direct beneficial ownership for the Master Fund due to its inability to vote or dispose of the securities directly.
Treace Medical Concepts Insider Bought Shares Worth $375,505, According to a Recent SEC Filing
This article reports on an insider purchase of Treace Medical Concepts shares. An insider recently bought shares worth $375,505, as disclosed in a recent SEC filing.
Treace Medical Concepts CEO John Treace buys $375,505 in shares By Investing.com
John T. Treace, CEO of Treace Medical Concepts (NASDAQ: TMCI), recently purchased approximately $375,505 worth of the company's common stock over three days in mid-May 2026. These purchases occurred at prices between $2.1739 and $2.6153 per share, preceding a significant stock rally. The CEO now directly holds over 7.15 million shares, and the company also reported better-than-expected Q1 2026 earnings despite a revenue decline.
Treace Medical Concepts CEO John Treace buys $375,505 in shares By Investing.com
John T. Treace, CEO of Treace Medical Concepts, recently purchased over $375,000 worth of company stock through multiple open market transactions. These purchases occurred days before a significant stock rally and were detailed in an SEC filing. The company also recently reported first-quarter 2026 earnings that surpassed analyst expectations, despite a year-over-year revenue decline.
TMCI (TMCI) CEO John Treace purchases over 150,000 company shares in open market
Treace Medical Concepts, Inc. CEO John T. Treace recently made open-market purchases of 153,763 company shares over three days, totaling approximately $375,505. These transactions increased his direct ownership to 7,158,313 shares, including restricted stock units. This insider buying activity is generally viewed positively, signaling confidence from the CEO in the company's prospects.
Treace Medical Concepts Insider Bought Shares Worth $375,505, According to a Recent SEC Filing
An insider at Treace Medical Concepts (TMCI) has reportedly purchased shares valued at $375,505, as disclosed in a recent SEC filing. The article highlights this significant insider transaction for the medical technology company. Treace Medical Concepts specializes in devices for bunion and midfoot deformity correction, including its patented Lapiplasty 3D Bunion Correction System.
Treace Medical Concepts, Inc. Shareholders Are Encouraged
Johnson Fistel, PLLP is investigating potential claims on behalf of investors in Treace Medical Concepts, Inc. (NASDAQ: TMCI) following a sharp decline in stock price after the company reported revised 2025 financial outlook. The investigation focuses on whether Treace's executive officers complied with federal securities laws after disclosing lower-than-expected revenue growth, shifts in surgeon preferences, and macroeconomic impacts on elective procedures. Investors who suffered losses are encouraged to contact Johnson Fistel for more information.
Treace Medical Concepts (TMCI) Price Target Decreased by 35.65% to 5.58
This article reports a significant price target decrease for Treace Medical Concepts (TMCI), falling to $5.58, which represents a 35.65% reduction. The information is sourced from MSN.
Treace Medical Concepts (TMCI) Q4 Loss Narrowing To US$0.15 EPS Tests Bearish Narratives
Treace Medical Concepts (TMCI) reported its Q4 FY 2025 results with revenue of US$62.5 million and a narrowed basic EPS loss of US$0.15, compared to earlier quarterly losses. While trailing 12-month revenue was US$212.7 million, the company still posted a net loss of US$59.0 million, with revenue growth of about 4% annually. The article discusses both bullish arguments, focusing on narrowing quarterly losses and a low P/S ratio, and bearish concerns regarding ongoing losses and modest revenue growth relative to the industry.
Treace Medical Concepts: Q1 Earnings Snapshot
Treace Medical Concepts Inc. (TMCI) reported a first-quarter loss of $18 million, or 28 cents per share. The medical device maker generated $47.2 million in revenue for the period. The company projects full-year revenue to be between $202 million and $212 million.
Earnings call transcript: Treace Medical Concepts beats Q1 2026 forecasts
Treace Medical Concepts (TMCI) reported better-than-expected Q1 2026 results, with EPS of -$0.28 against a -$0.31 forecast and revenue of $47.2 million, surpassing estimates of $45.86 million, despite a 10% year-over-year revenue decline. The company's stock rose 7.29% in pre-market trading, driven by strong gross margins and a 5% reduction in operating expenses. Treace Medical affirmed its full-year 2026 revenue guidance of $202 million to $212 million, anticipating improved revenue trends in the latter half of the year due to new product launches and increased market penetration.
Treace Medical Concepts: Q1 Earnings Snapshot
Treace Medical Concepts Inc. (TMCI) reported a first-quarter loss of $18 million, or 28 cents per share. The orthopedic medical device company generated $47.2 million in revenue for the period. Treace Medical Concepts anticipates full-year revenue to be between $202 million and $212 million.
Press Release: Treace Medical Concepts Reports First Quarter 2026 Financial Results
Treace Medical Concepts, Inc. announced its financial results for the first quarter of 2026. The company reported record revenue and provided an update on its strategic priorities and outlook for the year.
Treace Medical (NASDAQ: TMCI) Q1 2026 sales fall 10% as losses widen
Treace Medical Concepts reported a 10% decline in Q1 2026 revenue to $47.2 million, with net loss widening to $18.0 million and Adjusted EBITDA loss increasing to $5.5 million. Despite the wider losses and revenue pressure, the company reaffirmed its full-year 2026 revenue guidance ($202–$212 million) and Adjusted EBITDA loss outlook ($4–$6 million), citing solid liquidity with $51.9 million in cash and access to a $115 million credit facility. Management highlighted new product launches and an expanded patent portfolio, expecting a reduction in cash usage and a return to stronger growth in the latter half of the year.
Treace Medical Concepts: Q1 Earnings Snapshot
Treace Medical Concepts Inc. (TMCI) reported a first-quarter loss of $18 million, or 28 cents per share. The orthopedic medical device maker generated $47.2 million in revenue for the period and projects full-year revenue to be between $202 million and $212 million.
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Receives Consensus Recommendation of "Reduce" from Analysts
Seven analysts have issued a "Reduce" consensus recommendation for Treace Medical Concepts, Inc. (NASDAQ:TMCI), with an average 12-month price target of $4.77. The company is currently unprofitable, with a negative ROE and net margin, and shares are trading around $1.86. Institutional investors own 84.08% of the stock, with some recently making small additions to their holdings.
TMCI SEC Filings - Treace Medical Concepts, Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Treace Medical Concepts (TMCI) SEC filings, including annual reports (10-K), quarterly reports (10-Q), material event reports (8-K), and insider trading forms (Form 4). It details the company's focus on bunion and midfoot deformities and how these filings offer transparency into financials, governance, and risk factors for investors. The platform also features AI-powered summaries to help users quickly understand the implications of these regulatory disclosures.
Treace Medical Concepts (TMCI) to Release Earnings on Friday
Treace Medical Concepts (TMCI) is scheduled to release its Q1 2026 earnings before market open on Friday, May 8th, with analysts expecting an EPS of ($0.31) and revenue of $45.96 million. The company remains unprofitable, having posted a negative return on equity and net margin in the previous quarter. Analysts forecast a -$1 EPS for the current and next fiscal year, and institutional investors own approximately 84% of the stock.
Weber Capital Management LLC ADV Invests $1.45 Million in Treace Medical Concepts, Inc. $TMCI
Weber Capital Management LLC ADV recently invested $1.45 million in Treace Medical Concepts, Inc. (TMCI), acquiring 589,617 shares, making it their 13th largest holding and representing 0.93% of the company. Despite this institutional investment, analyst sentiment toward TMCI is generally weak, with a consensus "Reduce" rating and an average target price of $4.77. The company's stock trades near $1.98 with a market capitalization of $128.26 million, and it reported negative EPS and margins.
Treace Medical Concepts (NASDAQ:TMCI) Upgraded to Sell at Wall Street Zen
Wall Street Zen upgraded Treace Medical Concepts (NASDAQ:TMCI) from "strong sell" to "sell." Despite this upgrade, the company still holds a consensus "Reduce" rating and a target price of $4.77. The company recently reported Q4 EPS of -$0.15, meeting estimates, and revenue of $62.52 million, slightly exceeding predictions.
Treace Medical Concepts, Inc. to Release First Quarter 2026 Financial Results and Host Conference Call
Treace Medical Concepts, Inc. announced it will release its first quarter 2026 financial results on May 8, 2026, before market open, followed by a conference call at 8:00 am ET. The company specializes in surgical treatments for bunions and midfoot deformities with its Lapiplasty® 3D Bunion Correction® System. The announcement also included recent hedge fund activity, with notable increases and decreases in institutional holdings for TMCI shares, and analyst ratings, showing one firm issuing a "Sell" rating and a median price target of $5.0.
Treace to Report First Quarter 2026 Financial Results on May 8, 2026
Treace Medical Concepts, Inc. (NasdaqGS: TMCI) announced it will release its first-quarter 2026 financial results on May 8, 2026, before market open. The company will host a conference call at 8:00 AM ET to discuss the results, with registration details and webcast available on its investor relations website. Treace is a medical technology company focused on surgical treatments for bunions and midfoot deformities.
Before markets open May 8, Treace will post results and hold an 8 a.m. ET call
Treace Medical Concepts (TMCI) will release its first-quarter 2026 financial results before the market opens on May 8, 2026. The company will also host a conference call at 8:00 AM ET on the same day to discuss these results. Investors can register to join the call and access a live and archived webcast on Treace's investor relations website.
Treace Medical Concepts Inc. (TMCI) Stock Price | Live Quotes & Charts | NASDAQ
This page provides live stock quotes and charts for Treace Medical Concepts Inc. (TMCI), showing its current price of $1.91, up $0.04 (2.14%). It highlights that there are currently no analyst ratings or earnings information available for TMCI, and it features a promotional offer for stock trading alerts and educational content.
Treace Medical Concepts (TMCI) price target increased by 12.28% to 4.08
This article reports that the price target for Treace Medical Concepts (TMCI) has been increased by 12.28% to 4.08.
Treace Medical Concepts (TMCI) CFO reports 11,547-share tax withholding
Treace Medical Concepts (TMCI) CFO Mark Hair reported a tax-related disposition of 11,547 shares to cover tax obligations. This transaction, classified as a tax withholding, is a routine administrative event and not an open-market sale. After this, Hair retains 952,002 shares, including 786,691 restricted stock units.
Treace Medical Concepts, Inc. (TMCI) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before June 10, 2025
Levi & Korsinsky, LLP has filed a class action securities lawsuit against Treace Medical Concepts, Inc. (NASDAQ: TMCI). The lawsuit alleges that the company made misleading statements to investors regarding competition affecting demand for its "Lapiplasty" product, leading to a decline in revenue. Investors who suffered losses between May 8, 2023, and May 7, 2024, are urged to contact the firm before June 10, 2025, to learn about their rights to recover losses.
Treace Medical Concepts (TMCI) price target increased by 12.28% to 4.08
The article reports that the price target for Treace Medical Concepts (TMCI) has been increased by 12.28%, raising it to 4.08. No further details about the reasons for this change or the analyst responsible are provided in the snippet.
Treace Medical Concepts (TMCI) price target increased by 12.28% to 4.08
This article reports that the price target for Treace Medical Concepts (TMCI) has been increased by 12.28%, reaching $4.08. This adjustment suggests a more optimistic outlook by analysts for the company's stock performance.
Treace Medical Concepts (TMCI) price target increased by 12.28% to 4.08
The price target for Treace Medical Concepts (TMCI) has been increased by 12.28% to 4.08. This adjustment reflects an updated valuation for the company's stock.
Wall Street Zen Upgrades Treace Medical Concepts (NASDAQ:TMCI) to Sell
Wall Street Zen has upgraded Treace Medical Concepts (NASDAQ:TMCI) from a "strong sell" to a "sell" rating, despite the company's persistent fundamental weaknesses including negative EPS, net margin, and ROE. Overall analyst sentiment remains bearish, with a consensus "Reduce" rating and a target price of $4.77. The article highlights recent analyst downgrades, institutional trading activity, and the company's focus on its Lapiplasty 3D Bunion Correction System.
Treace Medical Concepts Announces Leadership Transition and Outlook
Treace Medical Concepts announced a leadership transition, with Chief Commercial Officer Gaetano M. Guglielmino departing and his duties redistributed. The company also reported preliminary unaudited revenue for Q1 2026 between $47.0 million and $47.2 million, and updated its 2026 revenue outlook to $202 million to $212 million. Analysts currently rate TMCI as a Hold with a $1.00 price target, and TipRanks’ AI Analyst, Spark, rates it as Neutral due to persistent losses and a bearish technical trend.
Stifel maintains Hold on Treace Medical stock, $3 target unchanged
Stifel reiterated a Hold rating on Treace Medical Concepts Inc. (NASDAQ: TMCI) with an unchanged price target of $3.00, despite the stock being down 81% over the past year. The firm noted that first-quarter sales still represent a year-over-year decline but expressed encouragement that management is setting reasonable targets. Investors should consider that the company is quickly burning through cash, highlighting a key challenge in its turnaround process.
Treace Medical Concepts, Inc. Reports Q1 2026 Results and Financial Outlook in SEC Form 8-K Filing 10
Treace Medical Concepts, Inc. has announced preliminary Q1 2026 revenue between $47.0 million and $47.2 million, alongside an updated full-year 2026 revenue guidance of $202 million to $212 million, an increase from the previous range. The company also reported a healthy cash position of approximately $51.9 million and the departure of officer Gaetano M. Guglielmino, who will transition to a consulting role. These updates were disclosed in a recent SEC Form 8-K filing.
Treace Medical Concepts Inc - preliminary Q1 2026 revenue expected at $47.0 million-$47.2 million - SEC filing
Treace Medical Concepts Inc. (TMCI) announced preliminary revenue expectations for Q1 2026, forecasting figures between $47.0 million and $47.2 million, according to an SEC filing. The medical technology company, specializing in bunion and midfoot deformity correction systems, published this update on April 9, 2026. This financial outlook provides insights into the company's performance for the first quarter of the year.
Treace Medical Concepts Inc - Preliminary Q1 2026 Revenue Expected At $47.0 Million-$47.2 Million - SEC Filing
Treace Medical Concepts Inc. has announced its preliminary revenue expectations for Q1 2026, forecasting figures between $47.0 million and $47.2 million. This information was disclosed in an SEC filing. The announcement was made through Reuters and reported via TradingView News.
[ARS] TREACE MEDICAL CONCEPTS, INC. SEC Filing
This article announces an SEC ARS filing by Treace Medical Concepts, Inc. (TMCI) on April 6, 2026. The filing is categorized with a low impact and neutral sentiment. The article also provides recent news and SEC filings related to TMCI, as well as key stock data for the company.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Treace Medical Concepts, Inc. (TMCI) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Treace Medical Concepts, Inc. (NASDAQ:TMCI) for potential corporate wrongdoing. The firm is encouraging shareholders who purchased Treace Medical securities before May 8, 2023, and still hold them, to join the investigation. Bronstein, Gewirtz & Grossman, LLC represents investors on a contingency fee basis and seeks to recover capital and ensure corporate accountability.
Treace Announces First Surgical Cases with the SuperBite™ Compression Screw System
Treace Medical Concepts, Inc. announced the successful completion of the first surgical cases utilizing its new SuperBite™ Compression Screw System. This system is designed to expand Treace's market presence beyond bunion and midfoot deformities to a broader range of foot and ankle procedures. Full commercialization is expected in Q3 2026, aiming to increase the company's addressable market.
Treace Announces First Surgical Cases with the SuperBite™ Compression Screw System
Treace Medical Concepts, Inc. announced the successful completion of the first surgical cases using its new SuperBite™ Compression Screw System. This system, designed for advanced compression with self-drilling and countersinking features, expands Treace's product portfolio for foot and ankle surgeries. The company anticipates full commercialization in Q3 2026, expecting it to increase their addressable market and accelerate case volumes.
Treace Announces First Surgical Cases with the SuperBite™ Compression Screw System
Treace Medical Concepts, Inc. announced the successful completion of the first surgical cases utilizing its new SuperBite™ Compression Screw System. This system is designed for advanced compression in foot and ankle surgeries, offering various screw diameters for a broad range of applications. The company anticipates full commercialization in Q3 2026, expecting it to expand their addressable market and accelerate case volumes.
Treace Announces First Surgical Cases with the SuperBite™ Compression Screw System
Treace Medical Concepts, Inc. announced the successful completion of the first surgical cases using its new SuperBite™ Compression Screw System, designed for a wide range of foot and ankle procedures. This new system features advanced compression technology and streamlined insertion, expanding Treace's market-leading portfolio and increasing its addressable market and customer base. Full commercialization is expected in the third quarter of 2026, with Dr. Anne Holly Johnson praising its effectiveness.
Treace Announces First Surgical Cases with the SuperBite™ Compression Screw System
Treace Medical Concepts, Inc. announced the successful completion of the first surgical cases utilizing its SuperBite™ Compression Screw System. The system features screws designed for advanced compression and a broad range of foot and ankle surgical applications. This new product is expected to expand Treace's addressable market and accelerate case volumes, with full commercialization anticipated in Q3 2026.
